23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe cuts 40% of its workforce, discontinues all therapy programs
(Reuters) -Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells. It also has a therapeutic antibody that targets the ULBP6 gene, which suppresses the immune activity of cells.
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline
The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
Hosted on MSN6h
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief ...
pharmaphorum2h
23andMe ends drug development and slashes staff
Me's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping ...
FierceBiotech12h
23andMe shutters cancer drug research programs, lays off 40% of staff
23andMe is shutting down its therapeutics development division, and plans to seek out buyers to find a new home for its ...
STAT1d
The end of 23andMe’s drug discovery dream
23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business ...
newsbytesapp.com3h
DNA-testing site 23andMe is slashing its workforce by 40%
23andMe, a leading name in the genetic testing business, has revealed plans to lay off some 200 employees, or nearly 40% of ...
Federal law could prevent your 23andMe data deletion, but you should still try
Requesting deletion closes your account permanently and prevents your data from being used in further research (existing ...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 millionDiscontinues development of therapeutics division and ...
CTV News9h
23andMe cuts 40 per cent of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40 per cent, or 200 employees, from its workforce and ...
Yahoo Finance4d
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe ...